Pipeline

Marina Biotech's platform and capabilities have unique potential for addressing the complexities of treating rare diseases. While our Familial Adenomatous Polyposis clinical program is advancing, we are also expanding our clinical pipeline to address myotonic dystrophy and Duchenne's muscular dystrophy.

Rare Disease Strategy

Receive approval for and commercialize CEQ508 for FAP in the United States